Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 2/20 | 0.57 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.57 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.57 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.57 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.57 |
| ▸ | NOTUM | Q6P988 | 3/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.38 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.37 |
| ▸ | HTR3B | O95264 | 2/20 | 0.37 |
| ▸ | HTR3A | P46098 | 2/20 | 0.37 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.37 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11068888 | 0.83 | ADRB1 (0.70) | ADRB1CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL7292849 | 0.80 | NOTUM (0.38) | ADRB1CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL218554 | 0.79 | HTR3E (0.62) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL8204166 | 0.74 | ADRB1 (0.59) | ADRB1CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL2273801 | 0.73 | ADRB1 (0.58) | ADRB1CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL14336964 | 0.73 | ADRB1 (0.57) | ADRB1CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL1252295 | 0.73 | CHRM2 (0.57) | ADRB1CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL6588911 | 0.73 | MAPT (0.45) | ADRB1NOTUMFFAR4HTR1APHGDH | |
| SCHEMBL8318076 | 0.73 | CHRM2 (0.57) | ADRB1CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL2298329 | 0.72 | ABCG2 (0.48) | ADRB1PHGDHALDH1A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010022055-A2 | INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | AMGEN INC. (US) | 2010-02-25 | — | — | WO | claimed |
| WO-2007045622-A1 | OXAZOLO [4 , 5-B] PYRIDINE COMPOUNDS AS NITRIC OXIDE SYNTHASE INHIBITORS | NYCOMED GMBH (DE) | 2007-04-26 | — | — | WO | claimed |
| US-20100216790-A1 | IMIDAZOPYRIDINE-DERIVATIVES AS INDUCIBLE NO-SYNTHASE INHIBITORS | ALTANA PHARMA AG (DE) | 2010-08-26 | — | — | US | disclosed |
| US-7709488-B2 | Imidazopyridine-derivatives as inducible no-synthase inhibitors | ALTANA PHARMA AG (DE) | 2010-05-04 | — | — | US | disclosed |
| WO-2010022055-A2 | INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | AMGEN INC. (US) | 2010-02-25 | — | — | WO | disclosed |
| EP-1670796-B1 | IMIDAZOPYRIDINE-DERIVATIVES AS INDUCIBLE NO-SYNTHASE INHIBITORS | NYCOMED GMBH (DE) | 2008-06-25 | — | — | EP | disclosed |
| WO-2007045622-A1 | OXAZOLO [4 , 5-B] PYRIDINE COMPOUNDS AS NITRIC OXIDE SYNTHASE INHIBITORS | NYCOMED GMBH (DE) | 2007-04-26 | — | — | WO | disclosed |
| EP-1670796-A1 | IMIDAZOPYRIDINE-DERIVATIVES AS INDUCIBLE NO-SYNTHASE INHIBITORS | ALTANA Pharma AG (DE) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005030770-A1 | IMIDAZOPYRIDINE-DERIVATIVES AS INDUCIBLE NO-SYNTHASE INHIBITORS | ALTANA PHARMA AG (DE) | 2005-04-07 | — | — | WO | disclosed |
| US-5242919-A | Antiinflammatory agents or hypotensive agents | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1993-09-07 | — | — | US | disclosed |
| US-5055474-A | Antihypoxia, hypotensive, antiinflammatory agents; anoxia treatment | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1991-10-08 | — | — | US | disclosed |
| EP-0173331-B1 | 2,3-DIHYDRO-1H-INDENE DERIVATIVES, A PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1991-08-14 | — | — | EP | disclosed |
| US-4895847-A | ANTIHYPOXIC, ANTIINFLAMMATORY, HYPOTENSIVE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1990-01-23 | — | — | US | disclosed |
| US-4788130-A | ANTIHYDOXIC, HYPOTENSIVE, ANTIINFLAMMATORY AGENT | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1988-11-29 | — | — | US | disclosed |
| EP-0173331-A2 | 2,3-Dihydro-1H-indene derivatives, a process for preparing them and pharmaceutical compositions containing same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1986-03-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216790-A1 | IMIDAZOPYRIDINE-DERIVATIVES AS INDUCIBLE NO-SYNTHASE INHIBITORS | NOS2, NOS1, NOS3 | ADRB1 263/4885CHRM2 213/4885CHRM4 980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.